Cutia Therapeutics's revenue per share for the
six
months ended in Dec. 2024 was HK$0.64.
Cutia Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.97.
During the past 12 months, the average Revenue Per Share Growth Rate of Cutia Therapeutics was 32.10% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 395.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Cutia Therapeutics's Revenue per Share or its related term are showing as below:
HKSE:02487'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 395.3 Med: 395.3 Max: 395.3
Current: 395.3
During the past 4 years, Cutia Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 395.30% per year. The lowest was 395.30% per year. And the median was 395.30% per year.
HKSE:02487's 3-Year Revenue Growth Rate is ranked better than 99.24% of 786
companies
in the Biotechnology industry
Industry Median: 0.5
vs HKSE:02487: 395.30
Cutia Therapeutics Revenue per Share Historical Data
The historical data trend for Cutia Therapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cutia Therapeutics's Revenue per Share
For the Biotechnology subindustry, Cutia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Cutia Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.97
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics (HKSE:02487) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cutia Therapeutics Revenue per Share Related Terms
Thank you for viewing the detailed overview of Cutia Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02487 has been successfully added to your